OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, immunology, and infectious diseases; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins or peptides; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Spain, Ireland, Chile, and Mexico. The company was founded in 2007 and is headquartered in Miami, Florida.

Opko Health Inc.

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Opko Health today and set a price target of $3.00. Chen covers the Healthcare sector, fo...

H.C. Wainwright Sticks to Their Buy Rating for Opko Health (OPK)

Analysts are intrested in these 5 stocks: ( ($NEO) ), ( ($SPOT) ), ( ($OPK) ), ( ($APPN) ) and ( ($META) ). Here is a breakdown of their recent


Current Quarter	$-0.08	Next Quarter	$-0.07
Current Year	$-0.29	Next Year	$-0.29
QoQ Growth	+12.5%	YoY Growth	+0.0%
3Y EPS CAGR	+13.3%	Target Price	$2.58
Consensus	Buy	Upside	+100.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	OPK	$1.29	+1.57%	2.47M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	OPK	$1.29	+1.6%	2.47M
3
4
5
6

OPK

OPK

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Opko Health Inc. Data in Excel

Get Opko Health Inc. Data in Excel